Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus standard-dose abiraterone in metastatic hormone-sensitive prostate cancer
IRCT20120618010057N3Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abiraterone in prostate cancer (PCa) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: biochemical free survival. Started Apr 2022; status: completed.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20120618010057N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120618010057N3.